BMS-986144

BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection[1].

Product Specifications

CAS Number

[1606150-08-6]

UNSPSC

12352005

Target

HCV; HCV Protease; Isotope-Labeled Compounds

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection; Inflammation/Immunology

Solubility

10 mM in DMSO

Smiles

O=C([C@H]1N2C[C@@H](C1)OC3=NC=CC4=C3C=C(C(OC([2H])([2H])[2H])=C4)F)N[C@@]5(C[C@H]5/C=C\CC[C@H](C[C@H]([C@@H](C2=O)NC(OC(C)(C(F)(F)F)C)=O)CC)C)C(NS(C6(CC6)C)(=O)=O)=O

Molecular Formula

C40H48D3F4N5O9S

Molecular Weight

856.94

References & Citations

[1]Sun LQ, et al. Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection [published online ahead of print, 2020 Nov 23]. J Med Chem. 2020;10.1021/acs.jmedchem.0c01296.